Lyophilised powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-16. Anything still debated is marked as such rather than presented as settled.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
=== Legal status === Paclitaxel was approved for medical use in the European Union in 2008. In November 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Naveruclif, intended for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas and non-small cell lung cancer. The applicant for this medicinal product is Accord Healthcare S.L.U. Naveruclif was approved for medical use in the European Union in January 2024. In May 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Apexelsin, intended for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas and non-small cell lung cancer. The applicant for this medicinal product is WhiteOak Pharmaceutical B.V. Apexelsin was approved for medical use in the European Union in July 2024.
== Function == SLC1A2 / EAAT2 is a member of a family of the solute carrier family of proteins. The membrane-bound protein is the principal transporter that clears the excitatory neurotransmitter glutamate from the extracellular space at synapses in the central nervous system. Glutamate clearance is necessary for proper synaptic activation and to prevent neuronal damage from excessive activation of glutamate receptors. EAAT2 is responsible for over 90% of glutamate reuptake within the brain.
Patulin is an organic compound classified as a polyketide. It is named after the fungus from which it was isolated, Penicillium patulum. It is a white powder soluble in acidic water and in organic solvents. It is a lactone that is heat-stable, so it is not destroyed by pasteurization or thermal denaturation. However, stability following fermentation is lessened. It is a mycotoxin produced by a variety of molds, in particular, Aspergillus and Penicillium and Byssochlamys. Most commonly found in rotting apples, the amount of patulin in apple products is generally viewed as a measure of the quality of the apples used in production. In addition, patulin has been found in other foods such as grains, fruits, and vegetables. Its presence is highly regulated.
== DVD / VHS == Rick Stein Cooks Fish (1997 VHS, re-issued as a bonus on Seafood Odyssey DVD) Rick Stein's Taste of the Sea (1999 VHS release of 1995 broadcast) Rick Stein's Seafood Odyssey (1999 VHS and 2005 DVD) Rick Stein's Seafood Lovers Guide (2001 VHS) Rick Stein's Food Heroes (2003 VHS and 2005 DVD. DVD release also includes the six episodes of Rick Stein's Food Heroes, Another Helping, Series 1.) Rick Stein's French Odyssey (2007 DVD) Rick Stein's Mediterranean Escapes (2009 DVD) Rick Stein's Far Eastern Odyssey (2010 DVD) Rick Stein's Spain (2011 DVD) Rick Stein's India (2013 DVD) Rick Stein's Venice To Istanbul (2015 DVD) Rick Stein's Tastes of the World: From Cornwall to Shanghai (2016 DVD - a compilation of six individual broadcasts: Rick Stein's Taste of Shanghai, Rick Stein's German Odyssey, Rick Stein & The Japanese Ambassador Rick Stein Tastes the Blues, Rick Stein's Taste of the Italian Opera, Rick Stein's Cornish Christmas) Rick Stein's Long Weekends (2017 DVD) Rick Stein's Road to Mexico (2018 DVD) Rick Stein's Secret France (2019 DVD)
Review of a clinical trial by experts chosen by the study sponsor. These experts review the trials for scientific merit, participant safety, and ethical considerations. (NLM) Per protocol set (Valid Cases, Efficacy Sample, Evaluable Subjects Sample)
Sources: en.wikipedia.org
=== Scottish independence === Galloway had long supported devolution for Scotland, but opposed Scottish independence. In the run-up to the Scottish independence referendum, held on 18 September 2014, Galloway was dismissive of the official Better Together campaign because it also involved Conservatives and Liberal Democrats, and he believed its leader, Alistair Darling, to be ineffective. "My case isn't that Scotland couldn't be independent, but shouldn't", The Sunday Times quoted him as saying. He was among 200 public figures to sign a letter to The Guardian opposing independence in the run up to the referendum. Galloway's argument against independence was based on "class" over "nationality". He told Serena Kutchinsky in an interview for Prospect magazine: "If we lose this vote the possibility of a real Labour government, or any kind of Labour government, in the rest of UK will be gone". In 2013, Galloway began a series of public meetings in Scotland, using the slogan "Just Say Naw" to independence. On 11 September 2014, Galloway took part in Scotland Decides: The Big, Big Debate, an independence debate held in Glasgow and broadcast by the BBC during the evening. In July 2020, Galloway co-founded and established a cross-party Scottish unionist political coalition called Alliance 4 Unity (later re-named All for Unity). Its goal was to defeat the Scottish National Party and Scottish nationalism in general at the 2021 Scottish Parliament election, by tactical voting for any Scottish unionist candidates in the proportional vote on each Scottish electoral regions.
As mayor of Nuevo Cuscatlán, Bukele described himself as part of the "radical left" because he wanted "radical changes" ("cambios radicales") for El Salvador; he also stated that his family had always had significant connections with the Salvadoran political left. Bukele believed in social justice and the state obligation to guarantee Salvadorans the opportunity for "health, education, [and] productive infrastructure" ("salud, educación, [e] infraestructura productiva"). Some FMLN members criticized Bukele's work as a businessman, believing that it contradicted the "historic goal of the proletariat" ("papel histórico del proletariado"): eliminating capitalism. Since becoming president, Bukele has stated that he does not adhere to any specific political ideology. He has criticized the political left and right in El Salvador for dividing the country after the civil war. In an interview with Time's Vera Bergengruen, he stated that he did not consider himself either left- or right-wing. El Faro's editorial board has described Bukele as a "politician without an ideology" ("político sin ideología"). Despite Bukele's ostensible ideologic neutrality, some journalists and political analysts have described him as a populist, a right-wing populist, and a conservative. Bukele himself has received support from conservatives abroad in both Latin America and the United States, particularly for his anti-crime policies, as well as criticism for democratic backsliding and consolidating power.
Trump names himself as the headliner for the "Great American State Fair" semiquincentennial event, organized by Freedom 250, in Washington D.C., after several artists pull out over concerns that the event became politicized by Trump. Martina McBride, Young MC, Bret Michaels, and the Commodores were among the artists who pulled out. A revised lineup includes artists such as Flo Rida, Milli Vanilli, and Vanilla Ice. May 31 – The National Basketball Association announces that the logo for the Larry O'Brien Championship Trophy will be displayed on the basketball courts of Frost Bank Center in San Antonio, Texas, and Madison Square Garden in New York City for the upcoming NBA Finals between the San Antonio Spurs and New York Knicks, making it the first time the logo decal will be placed on the NBA court during the NBA Finals since 2009.
"Genius" – 3:43 "Half-Life" – 3:59 "Start Again" (Gerry Leonard) – 3:55 "On Her Mind" (Duncan Sheik, Mick Jones) – 4:11 "Such Reveries" – 5:00 "On a High" – 3:36 "Magazines" – 3:47 "For You" – 2:11 "Good Morning!" – 4:04 "Memento" – 3:47 "Shine Inside" – 10:19 Note: The American version of the album features the song "Chimera" after "Shine Inside" as part of the final track (6 minutes and 28 seconds into the track).
Natriuretic peptides comprise a family of 3 structurally related molecules: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP), encoded by a gene symbolized NPPC. These peptides possess potent natriuretic, diuretic, and vasodilating activities and are implicated in body fluid homeostasis and blood pressure control. Unlike ANP and BNP, CNP does not have direct natriuretic activity. This is because CNP is a selective agonist for the B-type natriuretic receptor (NPRB) whereas ANP and BNP are selective for the A-type natriuretic receptor (NPRA). It is synthesized and secreted from the endothelium in response to many stimuli, for example shear stress, similar to nitric oxide (NO), and certain proinflammatory cytokines.
Sources: en.wikipedia.org
=== Beta-blockers === Many of the common symptoms of hyperthyroidism, such as palpitations, trembling, and anxiety, are mediated by increases in beta-adrenergic receptors on cell surfaces. Beta blockers, typically used to treat high blood pressure, are a class of drugs that offset this effect, reducing the rapid pulse associated with palpitations, and decreasing tremor and anxiety. Thus, a person with hyperthyroidism can often obtain immediate temporary relief until the hyperthyroidism can be characterized with the Radioiodine test noted above, and more permanent treatment takes place. Note that these drugs do not treat hyperthyroidism or any of its long-term effects if left untreated, but rather, they treat or reduce only symptoms of the condition. Some minimal effect on thyroid hormone production also comes with propranolol, which has two roles in the treatment of hyperthyroidism, determined by the different isomers of propranolol. L-propranolol causes beta-blockade, thus treating the symptoms associated with hyperthyroidism, such as tremor, palpitations, anxiety, and heat intolerance. D-propranolol inhibits thyroxine deiodinase, thereby blocking the conversion of T4 to T3, providing some, though minimal, therapeutic effect. Other beta-blockers are used to treat only the symptoms associated with hyperthyroidism. Propranolol in the UK, and metoprolol in the US, are most frequently used to augment treatment for people with hyperthyroidism.
Travell preferred a 1.5-in hypodermic needle for trigger point therapy and used this needle for both injection therapy and dry needling. Travell never used an acupuncture needle. Travell had access to acupuncture needles but reasoned that they were far too thin for trigger point therapy. She preferred hypodermic needles because of their strength and tactile feedback: "A 22-gauge, 3.8-cm (1.5-in) needle is usually suitable for most superficial muscles. In hyperalgesic patients, a 25-gauge, 3.8-cm (1.5-in) needle may cause less discomfort, but will not provide the clear feeling of the structures being penetrated by the needle and is more likely to be deflected by the dense contraction knots that are the target... A 27-gauge needle, 3.8-cm (1.5-in) needle is even more flexible; the tip is more likely to be deflected by the contraction knots and it provides less tactile feedback for precision injection".
== History == Dexamethasone was first synthesized by Philip Showalter Hench in 1957. It was introduced for medical use in 1958. On 16 June 2020, the RECOVERY Trial announced preliminary results stating that dexamethasone improves survival rates of hospitalized patients with COVID-19 receiving oxygen or on a ventilator. Benefits were only observed in patients requiring respiratory support; those who did not require breathing support saw a worse survival rate than the control group, although the difference may have been due to chance. A preprint containing the full dataset was published on 22 June 2020, and demand for dexamethasone surged after the publication of the preprint. The preliminary report was published in The New England Journal of Medicine on 18 July 2020. The final report was published in February 2021. The World Health Organization (WHO) states that dexamethasone should be reserved for seriously ill and critical patients receiving COVID-19 treatment in a hospital setting, and the WHO Director-General stated that "WHO emphasizes that dexamethasone should only be used for patients with severe or critical disease, under close clinical supervision. There is no evidence this drug works for patients with mild disease or as a preventative measure, and it could cause harm." In July 2020, the WHO stated they were in the process of updating treatment guidelines to include dexamethasone or other steroids. In September 2020, the WHO released updated guidance on using corticosteroids for COVID-19.
== Religious figures == Samuel Provoost (1758), third Presiding Bishop of the American Episcopal Church John Beardsley (1761), Church of England clergyman in Canada; chaplain of the Loyal American Regiment Benjamin Moore (King's 1768), second bishop of the Episcopal Diocese of New York and president of Columbia College Philip Frederick Mayer (1799), Lutheran clergyman; founder of the Pennsylvania Bible Society, the first of its kind in the U.S. Henry Onderdonk (1805), second Episcopal bishop of Pennsylvania Jackson Kemper (1809), first missionary bishop of the Episcopal Church in the United States Benjamin Treadwell Onderdonk (1809), fourth bishop of the Episcopal Diocese of New York Richard Fish Cadle (1813), Episcopalian priest and first superior of Nashotah House Manton Eastburn (1817), fourth bishop of the Episcopal Diocese of Massachusetts Henry John Whitehouse (1821), second bishop of the Episcopal Diocese of Chicago George Washington Bethune* (1823), theologian and preacher John Chester Backus* (1830), Presbyterian minister Morgan Dix (1848), priest, theologian, rector of Trinity Church William Edmond Armitage (1849), second bishop of the Episcopal Diocese of Milwaukee George Franklin Seymour (1850), first bishop of the Episcopal Diocese of Springfield James DeKoven (1851), leader of the Anglo-Catholic movement in the Episcopal Church Marvin Vincent (1854), Presbyterian minister and professor at the Union Theological Seminary in the City of New York Daniel S.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It separates molecules by hydrophobicity, which is effective for distinguishing an intact peptide from truncated or chemically modified forms. A C18 column with an acidic water-organic mobile phase is a standard configuration.